Bacteremia Due to Staphylococcus AureusPhase 2CLOPI-SNAPNCT07384702
Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia
A Phase 2 study testing Clopidogrel and No antiplatelet treatment in people with Bacteremia Due to Staphylococcus Aureus, run by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla at 20 sites in Spain.
Trial summary
The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB). Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Bacteremia Due to Staphylococcus Aureus
- What is being tested?
- Clopidogrel and No antiplatelet treatment
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 230 participants
- Where
- 20 sitesSpain
- Study dates
- Jun 2026to Jun 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria:
- Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.
- Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.
- Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.
Who cannot join
- General Medical and Safety Factors:
- Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).
- Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).
- Pregnancy: Pregnant or breastfeeding women.
- High Risk of Bleeding or Hematologic Disorders:
- Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.
Show all 12Show fewer
- Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment.
- Coagulation parameters: Platelet count <50,000/mm³ or known coagulation disorders.
- Concomitant medications: Patients already receiving regular aspirin therapy, other P2Y12 inhibitors, or therapeutic-dose anticoagulants (prophylactic-dose heparin is permitted).
- Specific Diagnoses and Clinical Criteria:
- Endocarditis: Confirmed diagnosis or clinical suspicion of bacterial endocarditis. Sources indicate that exclusion of endocarditis is justified because the potential benefit of clopidogrel is expected during early phases of high bacterial burden, whereas bleeding risk increases with prolonged treatment or established deep-seated infections.
- Medical judgment: If the treating clinical team determines that participation in this domain is not in the patient's best interest.
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
20 sites in 1 country
Spain20 sites
Hospital General Universitario de Alicante
Alicante
Esperanza Merino de Lucas, D, +34966389146, merinoluc@gmail.com
H.U. Clinic
Barcelona
Alex Soriano Viladomiu, D, +34 932275708, asoriano@clinic.cat
H.U. Mutua Terrassa
Barcelona
Lucía Boix Palop, D, +34 936784872, lboix@mutuaterrassa.cat ; luciaboix@hotmail.com
Hospital del Mar
Barcelona
Maria M Montero, D, +34 932483251 ext. 3251, mmontero@psmar.cat
Hospital Universitario Bellvitge
Barcelona
Francesc Escrihuela-Vidal, D, +34932606948, fescrihuela@bellvitgehospital.cat
Hospital Universitario de la Santa Creu i Sant Pau
Barcelona
Sara Grillo, D, sarris.grillo@gmail.com
Hospital Universitario Vall d'Hebron
Barcelona
Nuria Fernández Hidalgo, D, +34 932746000 ext. 6090, nufernan@gmail.com
H.U. Reina Sofía
Córdoba
Isabel M Machuca Sánchez, D, +34 957 011 636, isabelm.machuca.sspa@juntadeandalucia.es
Hospital Universitario San Cecilio
Granada
Francisco Anguita Santos, D, +34 958992536, miparedro@gmail.com
H.U. Jerez de la Frontera
Jerez de la Frontera
Rubén Lobato Cano, D, +34 665 816 722, ruben.lobato27@gmail.com
Hospital Universitario La paz
Madrid
Beatriz Díaz Pollán, D, bdiazp@salud.madrid.org
Hospital Universitario La Princesa
Madrid
Carmen Sáez Béjar, D, +34 619515031, carmenmaria.saez@salud.madrid.org
Hospital Universitario Ramon y Cajal
Madrid
María D Corbacho, D, mariadolores.corbacho@salud.madrid.org
Hospital Universitario Son Espases
Palma de Mallorca
Luisa Martin Pena, D, marial.martin@ssib.es
Hospital Virgen Macarena
Seville, 41008
Esther Recacha Villamor, D, +34635927009, erecachavillamor@gmail.com
Alicia Rodríguez Fernández, D, alicia.rodriguez.fernandez.sspa@juntadeandalucia.es
H.U. Virgen del Rocío
Seville
José Molina Gil-Bermejo, D, +34 671590280, josemolinagb@gmail.com
Hospital Universitario Virgen de Valme
Seville
Nicolás Merchante Gutiérrez, D, +34 95501734, nicolasmerchante@gmail.com
Hospital Universitario Marqués de Valdecilla
Valdecilla
Francisco Arnaiz de las Revillas Almajano, D, +34 942202520 ext. 73263, francisco.arnaizlasrevillas@scsalud.es
Hospital Universitario Álvaro Cunqueiro
Vigo
Nuria Val Domíguez, D, nuria.val.dominguez@gmail.com
Hospital Universitario Lozano Blesa
Zaragoza
Jose Ramón Paño Pardo, D, +34 630585111, joserrapa@gmail.com
About this study
Official title: Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)
The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).
Read the detailed description
The CLOPI-SNAP study evaluates whether the administration of clopidogrel as adjunctive therapy improves clinical outcomes while maintaining an acceptable safety profile in hospitalized patients with Staphylococcus aureus bacteremia (SAB).
To be eligible for the SNAP platform (NCT 05137119), patients must meet at least two criteria: isolation of the Staphylococcus aureus complex from ≥1 blood culture and admission to a participating hospital at the time of eligibility assessment. SNAP is designed to concurrently evaluate multiple therapeutic strategies. Patients are randomly assigned to different concurrent treatment options that are currently considered acceptable in routine clinical practice; thus, standard-of-care therapy consists of approved antibiotics for the treatment of Staphylococcus aureus infection.
Specifically, patients participating in CLOPI-SNAP-adult patients with SAB enrolled in the SNAP platform-are randomized in a 1:1 ratio to receive either oral clopidogrel for 5 days, administered as a 300-mg loading dose on Day 1 followed by 75 mg once daily on subsequent days, or no antiplatelet therapy. The primary endpoint is the Desirability of Outcome Ranking (DOOR) assessed at Day 90, a hierarchical composite outcome integrating survival, clinical failure, infectious complications, and the occurrence of serious adverse events. The limited 5-day duration of clopidogrel administration is intended to focus its potential therapeutic benefit on the early phase of infection, characterized by high bacterial burden and systemic inflammation, while minimizing the risk of bleeding associated with prolonged antiplatelet exposure.
- Conditions
- Bacteremia Due to Staphylococcus Aureus
- Being tested
- Clopidogrel, No antiplatelet treatment
- Keywords
- bacteriemia, Staphylococcus aureus, adjunctive treatment, Platform trial, Clopidogrel, Desirability of Outcome Ranking
- Medical subject headings
- Staphylococcal Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ClopidogrelDrug
Also called antiplatelet arm
Oral clopidogrel 75 mg pills; 300 mg from domain reveal (day 1 of treatment), followed by 75 mg daily until day 5 of treatment inclusive (4 additional calendar days)
No antiplatelet treatmentDrug
Different concurrent antibiotic options currently approved for SAB
| Study group | Role | What they receive |
|---|---|---|
| Oral clopidogrel | Experimental | Oral clopidogrel 75 mg pills; 300 mg from domain reveal (day 1 of treatment), followed by 75 mg daily until day 5 of treatment inclusive (4 additional calendar days) added to different concurrent antibiotic options currently approved for SAB Receives: Drug: Clopidogrel |
| No antiplatelet treatment | Other | Patients receive different concurrent antibiotic options currently approved for SAB Receives: Drug: No antiplatelet treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Desirability of Outcome Ranking (DOOR)
Desirability of Outcome Ranking is an ordinal scale that classifies each patient's overall clinical outcome from 1 to 5, integrating survival, clinical response, and serious adverse events. DOOR 1 represents the most favorable outcome (alive with clinical cure or improvement and no serious adverse events); DOOR 2, clinical cure or improvement with serious adverse events; DOOR 3, alive with clinical failure and no serious adverse events; DOOR 4, clinical failure with serious adverse events; and DOOR 5, death, representing the least desirable outcome. Lower numerical values indicate more favorable overall clinical outcomes.
Measured: At day 90 from day 0.
Secondary outcomes (4)
Mortality
Dead of any cause
Measured: At day 14 and day 28 from day of assignment of study drug (day 0)
Length of stay of inpatient hospitalisation
Length of hospital stay in days from patient enrollment into the study to the time of hospital discharge or death
Measured: At day 90 from day 0.
Microbiological treatment failure
Defined as a positive S. aureus culture from a sterile site (deep tissue or abscess).
Measured: At day 14 and day 90 from day of assignment of study drug (day 0)
New foci of infection
Diagnosis of new infection foci, based on clinical, radiological, microbiological, or pathological findings.
Measured: At day 14 and day 90 from day of assignment of study drug (day 0)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Feb 2026
- Study startJun 2026 (estimated)
- Primary completionJun 2030 (estimated)
- Study completionJun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Bacteremia Due to Staphylococcus AureusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Parallel Assignment Randomized 1:1 to receive either oral clopidogrel for 5 days-administered as a 300 mg loading dose on Day 1 followed by 75 mg once daily on subsequent days-or no antiplatelet therapy (antibiotic treatment according to SNAP assignment).
- Masking
- None (open label)
- Enrolment
- 230 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Sponsor type
- University, hospital or other
- Collaborators
- University of Melbourne
- Responsible party
- Sponsor
- Investigators
- Jesús Rodriguez Baños, PhD, Study chair, Hospital Universitario Virgen Macarena
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07384702
- Sponsor's protocol ID
- CLOPI-SNAP
- Other IDs
- 2023-503582-35-00, 2023
- Acronym
- CLOPI-SNAP
- Status last verified
- Feb 2026
- First submitted
- 27 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The information will be made available upon completion of the study. During the study period and data preparation phase, the information will be under the custody and responsibility of the research team.
Publications
Campbell AJ, Anpalagan K, Best EJ, Britton PN, Gwee A, Hatcher J, Manley BJ, Marsh J, Webb RH, Davis JS, Mahar RK, McGlothlin A, McMullan B, Meyer M, Mora J, Murthy S, Nourse C, Papenburg J, Schwartz KL, Scheuerman O, Snelling T, Strunk T, Stark M, Voss L, Tong SYC, Bowen AC; Staphylococcus aureus Network Adaptive Platform Paediatric and Youth (SNAP-PY) working groupSNAP Global Trial Steering Committee. Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials. JAMA Pediatr. 2024 Oct 1;178(10):1066-1071. doi: 10.1001/jamapediatrics.2024.2697.
PubMed 39158898Mahar RK, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, Cheng MP, Daneman N, Goodman AL, Lee TC, Lewis RJ, Lumley T, McLean ARD, McQuilten Z, Mora J, Paterson DL, Price DJ, Roberts J, Snelling T, Tverring J, Webb SA, Yahav D, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8.
PubMed 39934879Boyles T, Bowen AC, Chomba R, Nel J, Davis JS, Tong SYC. Inclusion of a low- and middle-income country site in the Staphylococcus aureus Network Adaptive Platform trial: experiences from Johannesburg. Clin Microbiol Infect. 2025 Dec;31(12):1948-1950. doi: 10.1016/j.cmi.2025.06.032. Epub 2025 Jul 4. No abstract available.
PubMed 40618922Walls G, McGrath L, Herdman MT, Campbell AJ, Cheng MP, Marks M, Ten Oever J, Sahng E, Yahav D, Tong SYC, Goodman AL, Lim AG, Bloomfield M; Staphylococcus aureus Network Adaptive Platform Early Oral Switch Domain Specific Working Group. Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study. Clin Infect Dis. 2026 Apr 30;82(4):e635-e642. doi: 10.1093/cid/ciaf522.
PubMed 40988120de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL; SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee; SNAP Trial Group. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2024 Oct 15;79(4):871-887. doi: 10.1093/cid/ciad666.
PubMed 37921609
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 2 Platform Randomized, Multicentre and Open Trial on the Efficacy and Safety of Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia (CLOPI-SNAP)
- ClinicalTrials.gov ID
- NCT07384702
- Acronym / sponsor ID
- CLOPI-SNAP / CLOPI-SNAP
- Conditions
- Bacteremia Due to Staphylococcus Aureus
- Keywords
- bacteriemia, Staphylococcus aureus, adjunctive treatment, Platform trial, Clopidogrel, Desirability of Outcome Ranking
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 230 participants (estimated)
- Lead sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en SevillaUniversity, hospital or other
- Collaborators
- University of Melbourne
- Study start
- Jun 2026 (estimated)
- Primary completion
- Jun 2030 (estimated)
- Study completion
- Jun 2030 (estimated)
- First posted
- 3 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The CLOPI-SNAP study is a randomized, multicenter, open-label clinical trial embedded within the SNAP (NCT 05137119) research platform. It constitutes a sub-study added to the core protocol for patients suffering Staphylococcus aureus bacteremia (SAB).
Detailed description
The CLOPI-SNAP study evaluates whether the administration of clopidogrel as adjunctive therapy improves clinical outcomes while maintaining an acceptable safety profile in hospitalized patients with Staphylococcus aureus bacteremia (SAB).
To be eligible for the SNAP platform (NCT 05137119), patients must meet at least two criteria: isolation of the Staphylococcus aureus complex from ≥1 blood culture and admission to a participating hospital at the time of eligibility assessment. SNAP is designed to concurrently evaluate multiple therapeutic strategies. Patients are randomly assigned to different concurrent treatment options that are currently considered acceptable in routine clinical practice; thus, standard-of-care therapy consists of approved antibiotics for the treatment of Staphylococcus aureus infection.
Specifically, patients participating in CLOPI-SNAP-adult patients with SAB enrolled in the SNAP platform-are randomized in a 1:1 ratio to receive either oral clopidogrel for 5 days, administered as a 300-mg loading dose on Day 1 followed by 75 mg once daily on subsequent days, or no antiplatelet therapy. The primary endpoint is the Desirability of Outcome Ranking (DOOR) assessed at Day 90, a hierarchical composite outcome integrating survival, clinical failure, infectious complications, and the occurrence of serious adverse events. The limited 5-day duration of clopidogrel administration is intended to focus its potential therapeutic benefit on the early phase of infection, characterized by high bacterial burden and systemic inflammation, while minimizing the risk of bleeding associated with prolonged antiplatelet exposure.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Parallel Assignment Randomized 1:1 to receive either oral clopidogrel for 5 days-administered as a 300 mg loading dose on Day 1 followed by 75 mg once daily on subsequent days-or no antiplatelet therapy (antibiotic treatment according to SNAP assignment).
| Arm | Type | Receives |
|---|---|---|
| Oral clopidogrel | Experimental | Drug: ClopidogrelOral clopidogrel 75 mg pills; 300 mg from domain reveal (day 1 of treatment), followed by 75 mg daily until day 5 of treatment inclusive (4 additional calendar days) added to different concurrent antibiotic options currently approved for SAB |
| No antiplatelet treatment | Other | Drug: No antiplatelet treatmentPatients receive different concurrent antibiotic options currently approved for SAB |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- To be eligible, patients must meet the same criteria as those of the general SNAP platform, as well as the domain-specific criteria:
- Microbiological isolation: Presence of Staphylococcus aureus complex in at least one blood culture.
- Hospitalization status: The patient must be admitted to a participating hospital at the time of eligibility assessment.
- Time window: Eligibility assessment must be completed within 72 hours after collection of the initial blood culture.
Key exclusion criteria (12 listed)
- Allergies: Known hypersensitivity to thienopyridines (clopidogrel, prasugrel, ticlopidine).
- Clinical status: Inability to tolerate or take oral medications, and severe hepatic impairment (Child-Pugh Class C).
- Pregnancy: Pregnant or breastfeeding women.
- Active or recent bleeding: Significant bleeding or invasive procedures within the previous 7 days.
- Planned surgeries: Requirement for major surgical intervention within 10 days following study enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ClopidogrelAlso: antiplatelet armOral clopidogrel 75 mg pills; 300 mg from domain reveal (day 1 of treatment), followed by 75 mg daily until day 5 of treatment inclusive (4 additional calendar days) | Drug | Oral clopidogrel |
| No antiplatelet treatmentDifferent concurrent antibiotic options currently approved for SAB | Drug | No antiplatelet treatment |
Primary outcome
Desirability of Outcome Ranking (DOOR)
Time frame: At day 90 from day 0.
Desirability of Outcome Ranking is an ordinal scale that classifies each patient's overall clinical outcome from 1 to 5, integrating survival, clinical response, and serious adverse events. DOOR 1 represents the most favorable outcome (alive with clinical cure or improvement and no serious adverse events); DOOR 2, clinical cure or improvement with serious adverse events; DOOR 3, alive with clinical failure and no serious adverse events; DOOR 4, clinical failure with serious adverse events; and DOOR 5, death, representing the least desirable outcome. Lower numerical values indicate more favorable overall clinical outcomes.
4 secondary outcomes
Mortality
Time frame: At day 14 and day 28 from day of assignment of study drug (day 0)
Length of stay of inpatient hospitalisation
Time frame: At day 90 from day 0.
Microbiological treatment failure
Time frame: At day 14 and day 90 from day of assignment of study drug (day 0)
New foci of infection
Time frame: At day 14 and day 90 from day of assignment of study drug (day 0)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Background: PubMed 39158898Campbell AJ, Anpalagan K, Best EJ, Britton PN, Gwee A, Hatcher J, Manley BJ, Marsh J, Webb RH, Davis JS, Mahar RK, McGlothlin A, McMullan B, Meyer M, Mora J, Murthy S, Nourse C, Papenburg J, Schwartz KL, Scheuerman O, Snelling T, Strunk T, Stark M, Voss L, Tong SYC, Bowen AC; Staphylococcus aureus Network Adaptive Platform Paediatric and Youth (SNAP-PY) working groupSNAP Global Trial Steering Committee. Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials. JAMA Pediatr. 2024 Oct 1;178(10):1066-1071. doi: 10.1001/jamapediatrics.2024.2697.
- Background: PubMed 39934879Mahar RK, McGlothlin A, Dymock M, Barina L, Bonten M, Bowen A, Cheng MP, Daneman N, Goodman AL, Lee TC, Lewis RJ, Lumley T, McLean ARD, McQuilten Z, Mora J, Paterson DL, Price DJ, Roberts J, Snelling T, Tverring J, Webb SA, Yahav D, Davis JS, Tong SYC, Marsh JA; SNAP Global Trial Steering Committee. Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial. Trials. 2025 Feb 11;26(1):49. doi: 10.1186/s13063-024-08684-8.
- Background: PubMed 40618922Boyles T, Bowen AC, Chomba R, Nel J, Davis JS, Tong SYC. Inclusion of a low- and middle-income country site in the Staphylococcus aureus Network Adaptive Platform trial: experiences from Johannesburg. Clin Microbiol Infect. 2025 Dec;31(12):1948-1950. doi: 10.1016/j.cmi.2025.06.032. Epub 2025 Jul 4. No abstract available.
- Background: PubMed 40988120Walls G, McGrath L, Herdman MT, Campbell AJ, Cheng MP, Marks M, Ten Oever J, Sahng E, Yahav D, Tong SYC, Goodman AL, Lim AG, Bloomfield M; Staphylococcus aureus Network Adaptive Platform Early Oral Switch Domain Specific Working Group. Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study. Clin Infect Dis. 2026 Apr 30;82(4):e635-e642. doi: 10.1093/cid/ciaf522.
- Background: PubMed 37921609de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL; SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee; SNAP Trial Group. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol. Clin Infect Dis. 2024 Oct 15;79(4):871-887. doi: 10.1093/cid/ciad666.
- complete Snap platform trialLink provided by the sponsor.
- Individual participant dataSharing planned: No. The information will be made available upon completion of the study. During the study period and data preparation phase, the information will be under the custody and responsibility of the research team.
Related trials for Bacteremia Due to Staphylococcus Aureus
RecruitingPhase 4
Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia
RecruitingPhase 4
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Enrolling by invitationPhase 4
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Staphylococcus Aureus Bacteremia
RecruitingPhase 2
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
RecruitingPhase 4
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jesús Rodriguez Baños, PhD study chair
Hospital Universitario Virgen Macarena
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Clopidogrel and No antiplatelet treatment in people with Bacteremia Due to Staphylococcus Aureus, run by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla at 20 sites in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clara Rosso-Fernández, PhD (+34955012144, claram.rosso.sspa@juntadeandalucia.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Desirability of Outcome Ranking (DOOR) (time frame: At day 90 from day 0.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07384702, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.